Moderna Inc MRNA

Buzz on the Bullboards: Bombardier, world woes, a smart fridge, and top shelf weed

[FinancialOrb99]

MRNA’s efforts to expand its pipeline highlight the importance of diversification. MYNZ, with its proprietary diagnostics platform, is ahead of the curve in building a business model that meets global

[TurboFinance89]

Double bottom reversal confirmed, and MYNZ is gaining attention after its breakout. Favorable clinical progress and rising market interest highlight its high-growth potential.

[Jonathon Brown]

A highlight of the week was Bombardier (TSX:BBD), which reported impressive growth in its Q3 2024 results. read article.

[PressRelease]

CAMBRIDGE, MA / ACCESSWIRE / November 12, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one large employer in BioSpace's 2025 Best Places to Work report based on the Company's reputation and commitment to innovation."We are honored to be recognized by BioSpace as the...read article.

[PressRelease]

mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringesCanada is the fourth jurisdiction to approve mRESVIA following approvals in the U.S., Europe, and QatarCAMBRIDGE, MA / ACCESSWIRE / November 8, 2024...read article.

[PressRelease]

New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC)PHILADELPHIA, Nov. 8, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company...read article.

[PressRelease]

Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03Achieves year-to-date product sales of $2.2 billion; reiterates 2024 expected product sales of $3.0 to $3.5 billionInitiated dosing in two pivotal Phase 3 trials to assess efficacy of...read article.

[PressRelease]

Pre-clinical data demonstrate robust anti-tumor activity and a novel off-the-shelf approach for GPC3+ solid tumorsPHILADELPHIA, Nov. 5, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...read article.

[PressRelease]

Philadelphia, Pennsylvania--(Newsfile Corp. - November 3, 2024) - Grabar Law Office is investigating whether officers and directors of Moderna, Inc. (NASDAQ: MRNA) breached their fiduciary duties owed to the company. If you have held Moderna shares since prior to January 18, 2023, and would like...read article.

[PressRelease]

CAMBRIDGE, MA / ACCESSWIRE / October 31, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences:Guggenheim's Inaugural Healthcare Innovation Conference, on Tuesday, November 12th at 10:00am ETUBS Global Healthcare Conference, on...read article.

[PressRelease]

The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program, as the third Phase 3 trial for the investigational individualized neoantigen therapy, V940 (mRNA-4157), focused on earlier stages of cancer Merck (NYSE: MRK), known as MSD outside of the United...read article.

[PressRelease]

CAMBRIDGE, MA / ACCESSWIRE / October 24, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2024 Top Employers Survey for the tenth consecutive year. Moderna was recognized for its commitment...read article.

[PressRelease]

CAMBRIDGE, Masss. and LONDON, Oct. 23, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that Junaid Bajwa, M.D., has joined its London office as Senior Partner and Head of United Kingdom. In this role, Dr. Bajwa will play an integral role in advancing...read article.

[PressRelease]

CAMBRIDGE, MA / ACCESSWIRE / October 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 7, 2024 to report its third quarter 2024 financial results, and provide a corporate update.A live webcast of the...read article.

[PressRelease]

NEW YORK, NY / ACCESSWIRE / October 8, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/moderna-lawsuit-submission-form...read article.

[PressRelease]

NEW YORK, NY / ACCESSWIRE / October 8, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/moderna-lawsuit-submission-form...read article.